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Primary cardiac sarcomas are rare tumors with a median survival of 6–12 months. Data suggest that an aggressive multidisciplinary
approach may improve patient outcome. We present the case of a male who underwent resection of cardiac sarcoma three times
from the age of 32 to 34. This report discusses the malignant nature of cardiac sarcoma and the importance of postoperative
multidisciplinary care.

1. Introduction
Primary cardiac sarcomas comprise less than 1% of sarcomas,
75% being benign and fatal with location [1]. Symptoms
include arrhythmias and dyspnea due to pulmonary hypertension [2]. Delay in diagnosis occurs because symptoms do
not manifest until the mass is large enough to impede blood
flow. Resection is followed by monitoring for recurrence [3].
Failure to completely remove the tumor results in recurrence
within 6–12 months. Postoperative treatment is dictated by
morphology, location, and immunohistochemistries. 75%
occur within the left atrium, a positive prognostic factor [4].
We report a young patient who underwent resection and two
repeat resections for two recurrences.

2. Presentation 1
In March of 2009, a 32-year-old male presented with shortness of breath and chest pain. Cardiac enzymes were negative
and a CT scan revealed a large left atrial mass. A transthoracic
echocardiogram (TTE) confirmed the left atrial mass with
severely hypoechoic perimeters attached to the posterior
aspect of the left atrium. The patient was hemodynamically

unstable and complete resection was performed via sternotomy with transseptal exposure of the left atrium. The
tumor was attached to the free wall of the left atrium and the
undersurface of the mitral valve. The entire epicardium was
excised with the tumor over the left atrium, exposing the muscle of the left atrium to the inner atrium. Pathology revealed a
5.7 × 4.7 cm high grade sarcoma with evidence of muscle
differentiation and immunohistochemical studies revealed
strongly positive vimentin. The patient was discharged on
postoperative day seven with instructions to follow up with
the surgeon and an oncologist.

3. Presentation 2
In September of 2009 the patient presented with shortness of
breath, chest pain, and palpitations. He had not followed up
with an oncologist due to financial hardship. CT and MRI
scans revealed three lobular enhancing masses within the left
atrium. The largest, measuring 3.5 × 2.6 cm, was attached to
the lateral wall of the atrium and on the posterolateral leaflet
of the mitral valve, protruding into the left ventricle with
extension into the left inferior pulmonary vein. The second

2

Case Reports in Surgery

(a)

(b)

(c)

Figure 1: Presentation 2. (a) MRI showing mass in the left side of the heart pressing on the mitral valve (arrow head) and two other masses
in the left atrium indicated (asterisks). (b) TEE showing a mobile, echogenic mass (asterisk) in the left heart prolapsing through the mitral
valve (arrow) into the ventricle. (c) Nongated CT-scan captured the mass (arrow) in motion in the left side of the heart. LA: left atrium. LV:
left ventricle.
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Figure 2: Presentation 2. (a) Tumor in the posterior aspect of the left atrium (arrow). (b) Excised left atrial sarcoma.

mass was broad based posteriorly near the origin of the left
inferior pulmonary vein. The third mass was in the interatrial
septum (Figure 1). Liver and pulmonary metastases were
noted. TTE revealed the mass causing 2+ mitral regurgitation
with normal valvular morphology and an ejection fraction of
50% (Figure 1).
The patient underwent a redo-sternotomy with cardiopulmonary bypass. A transseptal en bloc resection was

performed including the posterior aspect of the pericardium,
the entire left atrium up to the left pulmonary veins, and
1 cm from the annulus of the mitral valve (Figure 2). The
mitral valve, at gross examination, did not have any involvement/infiltration of the tumor contrary to the TTE and
radiologic imaging and was left intact. The right atrium was
then resected up to the atrial septum into the coronary sinus
at the junction of the superior and inferior vena cavae.
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Figure 3: (a) Cellular neoplasm with infiltrative borders and necrosis (×10). (b) The high power (×40) reveals a cellular tumor with high
nuclear/cytoplasmic ratio, irregular hyperchromatic, pleomorphic nuclei exhibiting high mitotic activity with abnormal mitosis and giant
cells (arrow). Digital images captured with a digital camera (Olympus dp 20) attached to a microscope (Olympus b × 51).

Additional tumor extension along the pericardium was also
excised. The posterior left atrium was reconstructed using
bovine pericardial patch, including pulmonary vein inflow.
Bovine patch was utilized to reapproximate the right atrium
anteriorly.
Pathology revealed malignant fibrous histiocytoma, lobulated and invasive into the myocardial tissue, with mitosis band, signifying the differentiation of the tumors, and
strongly positive vimentin and CD68 stain (Figure 3). The
patient was discharged on postoperative day five on warfarin with oncology follow-up. Adjuvant chemotherapy was
administered with resolution of nodules in the liver and lung.
MRI in January 2010 and CT scan in December showed no
evidence of regrowth. The morphology and architecture of
the atria were well defined without any filling defects.

4. Presentation 3
A CT scan in March of 2011 revealed a 2.8 × 3.7 cm left atrial
recurrence 10 weeks after completion of chemotherapy. TTE
revealed an echogenic density in the left atrium originating in
the interatrial septum (Figure 4). Redo-sternotomy was performed with cardiopulmonary bypass. Tumor was resected
from the interatrial septum in the vicinity of the previously
placed patch, including the left superior and inferior pulmonary veins. Resection continued over the anterior leaflet of
the mitral valve annulus. Pathology confirmed negative
margins inferior to the interatrial septum, but microscopic
disease was noted on the posterior mass adjacent to the mitral
valve leaflet connecting to the ostium of the pulmonary veins.
Resection of the latter was impossible without resecting the
entire fibrous trigone of the heart and possible left pneumonectomy. The interatrial septum and the free wall of the
left and the right atrium were reconstructed with bovine pericardium. Pathology revealed a high-grade spindle cell and
pleomorphic sarcoma. The patient was discharged on postoperative day six.
The patient received adjuvant chemotherapy. The followup scans were negative for regrowth in the heart, but the
tumor had spread in the pulmonary cavity with extrathoracic

Figure 4: Presentation 3. CT-scan showing tumor of the intra-atrial
septum in the left atrium, nongated scan.

manifestations in the brain and liver. Chemotherapy and
radiation (Gamma Knife radiosurgery) were utilized in 2012,
with limited regrowth and partial response. Early 2013, the
patient was admitted into acute care there upon progressed to
multiorgan failure and expired on March 2013. The patient’s
survival after primary resection was 48 months.

5. Comments
This case demonstrates the aggressive nature of cardiac sarcoma. The completeness of resection is considered a primary
determinant to long-term survival. The goal is to achieve an
R0 resection with adequate margins if possible when there is
no evidence of extracardiac disease, or surgical debulking if
deemed unresectable [4]. Most left sided tumors are first seen
with heart failure and require prompt resection followed by
adjuvant chemotherapy including doxorubicin, ifosfamide,
gemcitabine, and docetaxel [5]. Positive prognostic indicators
are left sided location, mitotic rate less than 10 per high power
field and absence of necrosis on histology [6]. Postoperative
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chemotherapy decreases recurrence. Prophylactic resection
of this patient’s interatrial septum might have improved his
prognosis. With adjuvant therapy the patient remained in
remission for 18 months.
The malignant nature of these tumors is well established
and even after adjuvant therapy mortality is high [3]. Incomplete resection requires chemotherapy and radiation [4, 7].
Palliative radiation therapy is recommended if resection is
not feasible [4]. Sarcomas originating in a chamber other
than the left atrium demonstrate increased recurrence. Atrial
reconstruction with a pericardial patch is feasible to completely resect the tumor whereas ventricular growth and
involvement of the valve typically require transplantation [8].
The extracardiac manifestations in our report with brain
metastasis demonstrates the need for a multidisciplinary
approach to dealing with cardiac sarcomas [4, 7, 9].
This case is notable for the short interval to recurrence:
6 months between the first and second presentation and
4 months between completion of chemotherapy and the
diagnosed second recurrence. Completeness of resection at
first presentation is a positive feature in disease-free survival.
Without adjuvant chemotherapy recurrence of cardiac sarcomas increases, as demonstrated in this case. Recurrence of
primary cardiac sarcomas is common and close surveillance
with an oncologist is essential.
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